Summary:
- Mabylon AG, a Swiss company specializing in human-derived antibodies, raised CHF 30M in funding from private investors, including former Roche management and board members.
- The funding will be used to advance their lead program, MY006, a tri-specific antibody targeting peanut allergens, through a Phase Ia/b trial in 2027.
- Mabylon focuses on developing therapies for allergies, neurodegenerative diseases, and inflammation using human-derived antibodies for their superior therapeutic potential.
—
Rewritten Article:
Mabylon AG Secures CHF 30M in Funding for Human-Derived Antibody Research
Mabylon AG, a biotechnology company based in Schlieren, Switzerland, recently announced a successful funding round, raising CHF 30 million to further their research in human-derived antibodies. The funding was contributed by private investors, with significant support from former executives of Roche, a pharmaceutical giant.
The primary focus of this investment is to advance Mabylon’s lead program, MY006, a tri-specific antibody designed to neutralize peanut allergens. The company aims to complete a Phase Ia/b trial by 2027, with the ultimate goal of gathering comprehensive safety and efficacy data.
Under the leadership of CEO Alcide Barberis, Mabylon is dedicated to developing innovative therapies using naturally occurring human antibodies to address allergies, neurodegenerative diseases, and inflammation. Human-derived antibodies offer a significant advantage over traditional sources, such as animal models or artificial libraries, due to their superior therapeutic potential.
In the realm of allergy treatment, Mabylon’s antibodies, sourced from allergic patients, target specific disease-related epitopes, expanding the understanding of allergenic epitopes and their impact on disease progression.
With this recent funding boost, Mabylon is poised to make significant strides in the field of antibody research, paving the way for novel therapeutic solutions in various medical conditions.
